Table 2 Clinical outcomes of PTCy and ATG combination prophylaxis

CloB + ATG

(n = 30)

AML (n = 32)

MDS (n = 18)

MPN (n = 5)

MDS/MPN (n = 10)

Haploidentical (n = 54)

Matched (n = 12)

70% 18-month GRFS

23.3% aGvHD

0% extensive cGvHD

[8]

CloB

(n = 36)

43% 18-month GRFS

50% aGvHD

11% extensive cGvHD

PTCy + ATG

AML(n = 113)

ALL (n = 49)

MPAL (n = 4)

MDS (n = 18)

CML (n = 10)

NHL (n = 30)

MM (n = 1)

Haploidentical

48% 2-year GRFS

60.9% 2-year OS

54.8% 2-year DFS

16.6% 2-year NRM

30.7% aGvHD

31.2% cGvHD

[9]

PTCy + ATG (2 mg/kg) + CsA

(n = 233)

Unknown (n = 444)

Matched unrelated (10/10)

56.2% 1-year GRFS

78.3% 1-year OS

69.2% 1-year RFS

14.7% 1-year NRM

23.3% Grade II-IV aGvHD

8% Grade III-IV aGvHD

14.1% moderate/severe cGvHD

[10]

PTCy + ATG (4.5 mg/kg) + CsA

(n = 127)

53.5% 1-year GRFS

72.4% 1-year OS

66.1% 1-year RFS

17.3% 1-year NRM

16.5% Grade II-IV aGvHD

4.9% Grade III-IV aGvHD

5.4% moderate/severe cGvHD

PTCy + ATG

AML (n = 79)

Unknown (n = 78)

Haploidentical

35.7% 2-year GRFS

49.4% 2-year OS

44.6% 2-year RFS

36.6% 2-year NRM

26.3% Grade II-IV aGvHD

9.5% Grade III-IV aGvHD

19.9% moderate/severe cGvHD

[11]

PTCy (70 mg/kg) + ATG

(n = 33)

(1) age ≥ 65 years, or patients of any age with a history of cardiac events,

(2) AML (n = 37), MDS (n = 11), lymphoma (n = 8), MPN (n = 2)

Haploidentical

60% 2-year GRFS

68% 2-year OS

65% 2-year PFS

18% 2-year NRM

18% Grade II-IV aGvHD

0% Grade III-IV aGvHD

27% cGvHD

[12]

PTCy (100 mg/kg) + ATG

(n = 25)

33% 2-year GRFS

52% 2-year OS

46% 2-year PFS

33% 2-year NRM

17% Grade II-IV aGvHD

5% Grade III-IV aGvHD

29% cGvHD